Evidence map›Paper›PMID 37506083›Full record

ArticlePloS one2023

Impact of body composition on patient prognosis after SARS-Cov-2 infection.

Takayuki Yamamoto, Kazushi Sugimoto, Syuhei Ichikawa, Kei Suzuki, Hideki Wakabayashi, Kaoru Dohi, Norihiko Yamamoto

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takayuki YamamotoDepartment of General Medicine, Mie University Hospital, Tsu, Japan.
Kazushi SugimotoDepartment of Clinical Laboratory, Mie University Hospital, Tsu, Japan.
Syuhei IchikawaDepartment of General Medicine, Mie University Hospital, Tsu, Japan.
Kei SuzukiDepartment of Infectious Disease, Mie University Hospital, Tsu, Japan.
Hideki WakabayashiDepartment of General Medicine, Mie University Hospital, Tsu, Japan.
Kaoru DohiDepartment of Cardiology and Nephrology, Mie University Hospital, Tsu, Japan.ORCID 0000-0002-5078-6326
Norihiko YamamotoDepartment of General Medicine, Mie University Hospital, Tsu, Japan.ORCID 0000-0001-7801-0725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the first outbreak of coronavirus disease 2019 (COVID-19), it has been reported that several factors, including hypertension, type 2 diabetes mellitus, and obesity, have close relationships with a severe clinical course. However, the relationship between body composition and the prognosis of COVID-19 has not yet been fully studied.

methodsThe present study enrolled 76 consecutive COVID-19 patients with computed tomography (CT) scans from the chest to the pelvis at admission. The patients who needed intubation and mechanical ventilation were defined as severe cases. Patients were categorized into four groups according to their body mass index (BMI). The degree of hepatic steatosis was estimated by the liver/spleen (L/S) ratio of the CT values. Visceral fat area (VFA), psoas muscle area (PMA), psoas muscle mass index (PMI), and intra-muscular adipose tissue content (IMAC) were measured by CT scan tracing. These parameters were compared between non-severe and severe cases.

resultsSevere patients had significantly higher body weight, higher BMI, and greater VFA than non-severe patients. However, these parameters did not have an effect on disease mortality. Furthermore, severe cases had higher IMAC than non-severe cases in the non-obese group.

conclusionsOur data suggest high IMAC can be a useful predictor for severe disease courses of COVID-19 in non-obese Japanese patients, however, it does not predict either disease severity in obese patients or mortality in any obesity grade.

Indexed as

COVID-19Diabetes Mellitus, Type 2Body CompositionBody Mass IndexHumansIntra-Abdominal FatObesityPrognosisRetrospective StudiesSARS-CoV-2

Identifiers

PMID37506083
PMCPMC10381082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.